Pfizer lays off sales staffers in India amid marketing model revamp Pharmacy retail giant Walgreens looks to disrupt the clinical trials business BIO: 'Diversity candidates' and knowledge 'shortfalls': Women in biotech say 'I'm here to do my job' despite toxic tropes Screen addicts, rejoice: J&J Vision to roll out contact lenses designed for digital device fatigue Whistleblower suit: CVS prevented Part D members from accessing generics Kyowa Kirin weighing $1 billion asset sale: Bloomberg Another knock back for amyloid: Roche's approach to presymptomatic Alzheimer's ends in failure Senseonics' Eversense 180-day glucose sensor scores new European approval Covis' controversial Makena gets FDA hearing date in bid to stay on the market Doubling up: Checkpoint on track to expand indications for cancer drug approval request Aidoc nearly doubles funding with $110M haul for CT scan-reading AI FDA's drug manufacturing oversight lags as pandemic wears on Delimiting and delivering: Promontory co-founder 'can't hire fast enough' as small biotech expands vision Bank of America pledges $40M to expand access to primary care in underserved communities nationwide Featured Story | By Angus Liu Pfizer is reportedly slimming down its sales force in India to drive a digital transformation. But instead of voluntary retirement, some staffers have reportedly been unexpectedly fired. Pfizer abruptly terminated over 200 of its Indian sales reps June 6, a local online news network has reported. read more |
| |
|---|
|
Top Stories By Heather Landi Walgreens' healthcare ambitions continue to grow as the pharmacy retail giant expands its reach into clinical trials, leveraging its vast trove of patient data, its technology assets and its retail locations. Industry CRO veteran Ramita Tandon, who is leading the new business line, spoke with Fierce Healthcare to lay out Walgreens' clinical trials strategy. read more By Max Bayer Discussions and dialogues addressing efforts to increase diversity in biotech permeated this year's BIO, with new data indicating slight gains across the industry. Yet toxic tropes persist both in and out of the conference, underscoring how much room for improvement remains. read more By Conor Hale Johnson & Johnson Vision announced its Acuvue Oasys Max 1-Day lenses have received regulatory green lights in the U.S., Canada and Europe. read more By Paige Minemyer A newly unsealed whistleblower suit claims that multiple CVS Health subsidiaries coordinated to prevent members from accessing generic drugs in a bid to boost the bottom line. read more By Zoey Becker Kyowa Kirin Co., a Japanese specialty pharma company, is reportedly considering a $1 billion asset sale. read more By Nick Paul Taylor Roche's long-running attempt to show its anti-amyloid-beta antibody works very early in the Alzheimer's disease pathway has ended in defeat. The AC Immune-discovered candidate failed to improve outcomes in cognitively unimpaired individuals at high imminent risk for developing Alzheimer's symptoms. read more By Conor Hale Distributed globally by Ascensia Diabetes Care, the implantable blood sugar tracking system is designed to offer long-term wear while also requiring fewer calibrations with fingerstick glucose readings. read more By Zoey Becker Makena has been on the market for over ten years through the FDA's accelerated approval program despite findings of its ineffectiveness. Unlike some companies that have pulled their marketed meds, Covis Pharma isn't letting this one go. read more By James Waldron Interim phase 1 results have sustained Checkpoint Therapeutics’ hopes for a second indication for its lead anti-PD-L1 antibody. read more By Andrea Park Aidoc is on quite the hot streak. Just about two months after racking up its ninth FDA clearance for an artificial intelligence-powered radiology tool, the Israeli startup has re-upped its annual tradition of raising tens of millions of dollars. read more By Fraiser Kansteiner In fiscal year 2021, the FDA sent out 70% of follow-up letters to manufacturing facilities within 90 days of an inspection. Over that same stretch, the regulator completed 48% of regulatory actions for facilities in need of follow-up within six months of inspection closing, the agency said in a new report. Both represented declines from the prior year. read more By Gabrielle Masson Promontory Therapeutics has ditched its old name in an effort to “delimit” itself and is now doing what many others can’t—expanding. read more By Anastassia Gliadkovskaya The bank will partner with nonprofit community development financial institutions to expand community health and primary care centers. read more | 